Hongbo Lu - 11 Jun 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Reporting relationship: Director
Issuer ticker: TERN
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2025, 17:44:19 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ David Strauss, as Attorney-in-Fact for Hongbo Lu

Key filing fact

Hongbo Lu filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 12 Jun 2025.

Key facts

This page summarizes Hongbo Lu's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2025, 17:44.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767584 Primary reporting owner

Lu Hongbo

Relationship: Director
Address: C/O TERNS PHARMACEUTICALS, INC., 1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Signature: /s/ David Strauss, as Attorney-in-Fact for Hongbo Lu
Signature date: 12 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TERN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +45,000
Change %
Price: $0.000000
Shares after: 45,000
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $4.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.